Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2009

01-01-2009 | Original Article

Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study

Authors: Steven A. Grover, MD, MPA, FRCPC, Ilka Lowensteyn, PhD, Lawrence Joseph, PhD, Mohammed Kaouache, MSc, Sylvie Marchand, RN, Louis Coupal, MSc, Ghislain Boudreau, PhD

Published in: Journal of General Internal Medicine | Issue 1/2009

Login to get access

Abstract

Objectives

Hypertension is common among patients with dyslipidemia but is often poorly treated. The objective of this analysis was to evaluate how a decision aid, used by primary care physicians to improve lipid therapy, impacted on the treatment of hypertension.

Study Design

Data were analyzed from patients enrolled in a randomized trial focusing primarily on the treatment of dyslipidemia. Patients received usual care or a coronary risk profile every three months to monitor the risk reduction following lifestyle changes and/or pharmacotherapy to treat dyslipidemia. Hypertension management was assessed based on a post hoc analysis of individuals whose blood pressure exceeded current national hypertension guidelines.

Results

There were 2,631 subjects who completed the study. Among 1,352 patients without diagnosed hypertension, 30% were above target on at least three consecutive visits. Among 1,279 individuals with known hypertension, 69% were above target on at least two consecutive visits. Overall, patients receiving risk profiles were more likely to receive appropriate antihypertensive therapy (OR = 1.40, 95% CI 1.11 – 1.78) compared to those receiving usual care. After adjustment for inter-physician variability and potential confounders, the use of the risk profile was associated with an increased likelihood of starting therapy (OR = 1.78, 95% CI 1.06 – 3.00) or modifying therapy (OR = 1.40, 95% CI 1.03 – 1.91).

Conclusions

In this clinical trial of dyslipidemia management, inadequately controlled hypertension was common, occurring in nearly 50% of individuals. Ongoing coronary risk assessment was associated with more appropriate blood pressure management. Cardiovascular risk assessment decision aids should be further evaluated in a randomized trial of hypertension therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24:1601–10.PubMedCrossRef De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24:1601–10.PubMedCrossRef
2.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–72.PubMedCrossRef
3.
go back to reference Ramsay L, Williams B, Johnston G, MacGregor L, Potter J, Poulter N. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999;13:569–92.PubMedCrossRef Ramsay L, Williams B, Johnston G, MacGregor L, Potter J, Poulter N. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens. 1999;13:569–92.PubMedCrossRef
4.
go back to reference Khan NA, McAlister FA, Campbell NRC, et al. The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol. 2004;20:41–54.PubMed Khan NA, McAlister FA, Campbell NRC, et al. The 2004 Canadian recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol. 2004;20:41–54.PubMed
5.
go back to reference New Zealand Guidelines Group (NZGG). Assessment and management of cardiovascular risk. New Zealand Guidelines Group. 2003. New Zealand Guidelines Group (NZGG). Assessment and management of cardiovascular risk. New Zealand Guidelines Group. 2003.
6.
go back to reference Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.PubMedCrossRef Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.PubMedCrossRef
7.
go back to reference Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957–63.PubMedCrossRef Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957–63.PubMedCrossRef
8.
go back to reference Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;1345:479–86.CrossRef Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;1345:479–86.CrossRef
9.
go back to reference Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work (commentary). CMAJ. 2003;169:30–1.PubMed Majumdar SR, Soumerai SB. Why most interventions to improve physician prescribing do not seem to work (commentary). CMAJ. 2003;169:30–1.PubMed
10.
go back to reference Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease: A long and winding road. J Am Coll Cardiol. 2004;43:1738–42.PubMedCrossRef Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease: A long and winding road. J Am Coll Cardiol. 2004;43:1738–42.PubMedCrossRef
11.
go back to reference Sabaté E. Adherence to long-term therapies. Evidence for action. ISBN 92 4 154599 2, 1–199. 2003. Switzerland, World Health Organization. Sabaté E. Adherence to long-term therapies. Evidence for action. ISBN 92 4 154599 2, 1–199. 2003. Switzerland, World Health Organization.
12.
go back to reference McManus RJ, Mant J, Roalfe A, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. Br Med J. 2005;331:466–7.CrossRef McManus RJ, Mant J, Roalfe A, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. Br Med J. 2005;331:466–7.CrossRef
13.
go back to reference Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease and prevention guidelines. Circulation. 2005;111:499–510.PubMedCrossRef Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease and prevention guidelines. Circulation. 2005;111:499–510.PubMedCrossRef
14.
go back to reference Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. Circulation. 2002;106:388–91.PubMedCrossRef Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. Circulation. 2002;106:388–91.PubMedCrossRef
15.
go back to reference Grover SA, Lowensteyn I, Joseph L, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: The CHECK-UP Study: A randomized controlled trial. Arch Intern Med. 2007;167:2296–303.PubMedCrossRef Grover SA, Lowensteyn I, Joseph L, et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: The CHECK-UP Study: A randomized controlled trial. Arch Intern Med. 2007;167:2296–303.PubMedCrossRef
16.
go back to reference Fodor JG, Frohlich JJ, Genest Jr, McPherson PR, for the Working Group on Hypercholesterolemia and Other Dyslipidemia. Recommendations for the management and treatment of dyslipidemia. CMAJ.. 2000;162:1441–7.PubMed Fodor JG, Frohlich JJ, Genest Jr, McPherson PR, for the Working Group on Hypercholesterolemia and Other Dyslipidemia. Recommendations for the management and treatment of dyslipidemia. CMAJ.. 2000;162:1441–7.PubMed
17.
go back to reference Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA. 1992;267:816–22.PubMedCrossRef Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA. 1992;267:816–22.PubMedCrossRef
18.
go back to reference Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary vs. secondary prevention. Arch Intern Med. 1998;158:655–62.PubMedCrossRef Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary vs. secondary prevention. Arch Intern Med. 1998;158:655–62.PubMedCrossRef
19.
go back to reference Grover SA, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M. How accurately do Canadian physicians assess the coronary risk of their patients? The preliminary results of the Coronary Health Assessment Study (CHAS). BMJ. 1995;310:975–8.PubMed Grover SA, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M. How accurately do Canadian physicians assess the coronary risk of their patients? The preliminary results of the Coronary Health Assessment Study (CHAS). BMJ. 1995;310:975–8.PubMed
20.
go back to reference MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. CMAJ. 1992;146:1969–74.PubMed MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. CMAJ. 1992;146:1969–74.PubMed
21.
go back to reference Lee KJ, Thompson SG. Clustering by health professional in individually randomised trials. BMJ. 2005;330:142–4.PubMedCrossRef Lee KJ, Thompson SG. Clustering by health professional in individually randomised trials. BMJ. 2005;330:142–4.PubMedCrossRef
22.
go back to reference Sullivan LM, Dukes KA, Losina E. Tutorial in biostatistics. An introduction to hierarchical linear modelling. Stat Med. 1999;18:855–88.PubMedCrossRef Sullivan LM, Dukes KA, Losina E. Tutorial in biostatistics. An introduction to hierarchical linear modelling. Stat Med. 1999;18:855–88.PubMedCrossRef
23.
go back to reference Hall LML, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326:251–2.PubMedCrossRef Hall LML, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326:251–2.PubMedCrossRef
24.
go back to reference Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008 [Epub ahead of print]. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008 [Epub ahead of print].
25.
go back to reference Walsh JM, McDonald KM, Shojania KG, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44:646–57.PubMedCrossRef Walsh JM, McDonald KM, Shojania KG, et al. Quality improvement strategies for hypertension management: a systematic review. Med Care. 2006;44:646–57.PubMedCrossRef
26.
go back to reference Tu K, Davis D. Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow-up of hypertension. J Contin Educ Health Prof. 2002;22:11–22.PubMedCrossRef Tu K, Davis D. Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow-up of hypertension. J Contin Educ Health Prof. 2002;22:11–22.PubMedCrossRef
27.
go back to reference Hetlevik I, Holmen J, Kruger O. Implementing clinical guidelines in the treatment of hypertension in general practice. Evaluation of patient outcome related to implementation of a computer-based clinical decision support system. Scand J Prim Health Care. 1999;17:35–40.PubMedCrossRef Hetlevik I, Holmen J, Kruger O. Implementing clinical guidelines in the treatment of hypertension in general practice. Evaluation of patient outcome related to implementation of a computer-based clinical decision support system. Scand J Prim Health Care. 1999;17:35–40.PubMedCrossRef
28.
go back to reference Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ. 2000;320:686–90.PubMedCrossRef Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ. 2000;320:686–90.PubMedCrossRef
29.
go back to reference Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Work-site treatment of hypertension by specially trained nurses. A controlled trial. Lancet. 1979;2:1175–8.PubMedCrossRef Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Work-site treatment of hypertension by specially trained nurses. A controlled trial. Lancet. 1979;2:1175–8.PubMedCrossRef
31.
go back to reference Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover SA. Can Computerized Risk Profiles Help Patients Improve Their Coronary Risk? The Results of The Coronary Health Assessment Study (CHAS). Prev Med. 1998;27:730–7.PubMedCrossRef Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover SA. Can Computerized Risk Profiles Help Patients Improve Their Coronary Risk? The Results of The Coronary Health Assessment Study (CHAS). Prev Med. 1998;27:730–7.PubMedCrossRef
Metadata
Title
Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study
Authors
Steven A. Grover, MD, MPA, FRCPC
Ilka Lowensteyn, PhD
Lawrence Joseph, PhD
Mohammed Kaouache, MSc
Sylvie Marchand, RN
Louis Coupal, MSc
Ghislain Boudreau, PhD
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 1/2009
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0825-4

Other articles of this Issue 1/2009

Journal of General Internal Medicine 1/2009 Go to the issue

Reflection

Karen

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.